The role of AI in large-scale drug manufacturing

Advanced Process Control (APC)

AI-driven Advanced Process Control (APC) systems could become pivotal in maintaining the desired output quality during manufacturing. By integrating real-time sensor data with AI algorithms, these systems could dynamically adjust process parameters to maintain optimal conditions. This not only enhances product quality but also reduces the likelihood of production errors and downtime.

For instance, in a bioreactor used for drug production, AI can continuously monitor variables such as pH, temperature, and nutrient levels. If any parameter deviates from the optimal range, the AI system can automatically adjust inputs to bring the process back to the desired state, ensuring consistent product quality.

This could be applied to all aspects of production, from raw material handling to packaging. This not only speeds up production but also ensures higher consistency and quality of the final product.

AI systems can automatically adjust process parameters in real-time to maintain optimal conditions, reducing the likelihood of human error and improving overall efficiency.

Continuous improvement through trend monitoring

AI excels at identifying patterns and trends in complex datasets. In drug manufacturing, AI can monitor production trends to identify areas for continuous improvement. By analysing historical and real-time data, AI systems can suggest process adjustments that enhance efficiency, reduce costs, and improve overall product quality.

A potential use case could be the tracking of the performance of different batches of a drug and identify subtle variations in production conditions that lead to higher yields. By implementing these insights, manufacturers can continuously refine their processes to achieve better results.

This ensures that the production remains within specified parameters, leading to higher quality and compliance. For example, AI systems can continuously monitor critical quality attributes and process parameters, making real-time adjustments to maintain product quality.

Challenges

However, the integration of AI also presents challenges. There are concerns about hallucinations, data privacy and the need for robust cybersecurity measures to protect sensitive information.

One of the key risks of using AI in large-scale drug manufacturing is the potential for hallucinations, instances where AI generates false or misleading information that appears credible. In a manufacturing context, this could lead to incorrect process recommendations, flawed quality control insights, or inaccurate predictions about equipment performance.

If not carefully validated, such outputs could compromise product safety, regulatory compliance, or operational efficiency.

Closed agents

To mitigate this, AI systems must be rigorously tested, continuously monitored, and always used alongside expert human oversight. A closed agent can help prevent AI hallucinations by operating within a tightly controlled environment that limits exposure to unreliable or irrelevant data.

These systems are trained on curated, domain-specific datasets and follow strict operational rules, reducing the likelihood of generating false or speculative outputs. By incorporating human-in-the-loop oversight, closed agents ensure that critical decisions are reviewed and validated by experts before implementation. Their actions are fully traceable and auditable, which is essential for compliance in regulated industries.

Additionally, real-time monitoring and feedback mechanisms allow for immediate detection and correction of anomalies, further safeguarding against hallucinations and ensuring consistent, reliable performance.

Personnel and regulation

The complexity of AI systems requires skilled personnel for implementation and maintenance, which can be a barrier for some companies. Furthermore, regulatory frameworks must evolve to keep pace with AI advancements, ensuring that AI applications meet safety and quality standards. Balancing these benefits and challenges is crucial for the successful adoption of AI in pharmaceutical manufacturing.

Mitigating expense

Investing in AI for large-scale drug manufacturing involves significant financial burdens, particularly in the early stages. Costs include acquiring high-performance computing infrastructure, integrating AI with existing manufacturing systems, and hiring or training specialised talent.

Additionally, ongoing expenses for data management, model validation, cybersecurity, and regulatory compliance can be substantial. While the long-term benefits, such as improved efficiency and reduced waste can offset these costs, the upfront investment can be a barrier for many organisations, especially those with limited R&D budgets.

Maximising tax credits

R&D tax credits could play a crucial role in easing the financial burden of adopting AI in pharmaceutical manufacturing. Companies can claim a tax credit of 30% qualifying R&D expenditures. This incentive, combined with the standard 12.5% corporate tax deduction, can result in a net subsidy of over 40%.

For firms investing in AI infrastructure, data systems, and skilled personnel, these supports significantly reduce upfront costs and encourage long-term innovation within Ireland’s life sciences sector. Grants also have the potential to greatly reduce this burden. Additionally significant grants are available for feasibility studies, RD&I activities, and training; these could also help ease the cost of a transition to AI.  

Conclusion

AI's integration into the process development phase of drug manufacturing holds immense potential. From optimising process design and scale-up to enhancing supply chain resilience, AI-driven technologies are set to make drug manufacturing more efficient, reliable, and scalable.

As the pharmaceutical industry continues to embrace AI, we can expect significant advancements in the production of high-quality drugs, ultimately benefiting patients worldwide. Regulatory bodies are actively adapting to these trends, ensuring that AI can be safely and effectively integrated into pharmaceutical production.

Failing to adopt AI could lead to significant competitive and operational disadvantages. Without AI-driven optimisation, companies may face higher production costs, slower response times to market demands, and increased risk of quality control issues compared to their competitors.

Manual or outdated systems can also struggle to meet evolving regulatory standards and traceability requirements. Over time, this can erode market share, reduce profitability, and limit a company’s ability to innovate, especially as competitors leverage AI to streamline operations, reduce waste, and accelerate time-to-market.